Front Row Series 2: Daphne Koller on AI

In Part Three of this series on AI in Drug Discovery, Daphne Koller PhD, CEO and co-founder of insitro, discusses the application of AI to a rare liver disease

0

In Part Three of this series on AI in Drug Discovery, Daphne Koller PhD, CEO and co-founder of insitro, discusses the application of AI to a rare liver disease . . .

Get GEN Edge Today!

See More on the Edge

Continue reading this article and more
with a GEN Edge subscription

Start Your 30-Day Free Trial Now

Log In Join GEN Edge

Previous articlePeroxidasin—A New Target for Preventing Lung Cancer Caused by Air Pollution?
Next articleFront Row Series 2: Andy Beck on AI